Rights issue in Oasmia Pharmaceutical (SE) — SEK 239 million

Carnegie acted as adviser to Oasmia in the rights issue of SEK 239 million. Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase.November, 2010.